Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a business update and outlook for the development of its lead product ...

As previously announced Mendus AB (publ) (“Mendus”) has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed ...

Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties.

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and ...

Capturing the immunotherapy opportunity in myeloid blood cancers In the fourth quarter of 2025, Mendus presented continued positive long-term survival data of the ADVANCE II trial in acute myeloid leu ...

Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their ...

ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemia Registration trial preparations are ongoing, following positive initial FDA ...

The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment ...